"Spray Cryotherapy is an exciting addition to the tools offered at NYU as it is a minimally invasive (endoscopic) approach that is very patient friendly," says Dr. Bizekis. "We freeze and kill the unwanted tissue with very little pain and patients can generally return to work the next day. Some patients are not candidates for surgery or they have failed to respond to other treatments like chemotherapy and radiation and spray cryotherapy gives us another option. Recently published data also demonstrates it to be safe and effective as a first-line or primary therapy."
Spray cryotherapy utilizes ultra-cold (-196 degrees C) liquid nitrogen delivered in a low pressure spray to freeze and destroy unwanted tissue in the body.
"We are thrilled to have NYU as our 75th customer. It is fitting that such a world-class, patient centered, integrated academic medical center would mark a landmark event for the company" said Ric Hughen, Vice President-Sales & Marketing. "NYU joins a group of preeminent medical centers on the leading edge of new technology adoption for the benefit of their patients".
CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the CryoSpray Ablation System. The CSA System utilizes a patented spray cryogenic technology that allows a physician to freeze and destroy a wide range of unwanted tissues via an endoscope.
For more information, please contact Richard Hughen at rhughen@csamedical.com or www.CSAmedical.com.
SOURCE CSA Medical, Inc.
